肥胖在已開發國家中是個愈來愈重要的問題，其危機在於造成很多疾病的發生，在歐洲和美國有40%的人遭遇肥胖的問題，研究指出肥胖和愈來愈多疾病的發生有關，例如：高血壓、成人型糖尿病、癌症、心血管疾病。肥胖發生的原因很多，其中一個原因為幹細胞分化為脂肪細胞及脂肪細胞不斷儲存能量變大。有很多治療肥胖的方法：(i) 減少高卡路食物的吸收，(ii) 適當的運動，（iii）減少幹細胞分化為脂肪細胞。

有研究指出史達汀類的藥物能抑制脂肪前驅細胞分化成脂肪細胞而2-去氧葡萄糖能減少體內葡萄糖代謝。從人類脂肪組織中取得的幹細胞已被證明為間葉世系的幹細胞，能分化成成熟的脂肪細胞。在本篇論文中，我們選擇人類脂肪組織衍生幹細胞作為細胞模式研究史達汀類的藥物及2-去氧葡萄糖的抗脂肪分化影響。初步結果顯示史達汀類的藥物及2-去氧葡萄糖具有抑制幹細胞分化成脂肪細胞之活性。

Obesity is a more and more important issue in the developed countries. In Europe and the United States, 40% of people are obesity. Obesity is associated with many diseases such as hypertension, diabetes, cancer and cardiovascular diseases. One of the causes for obesity is that the stem cell is induced and differentiated into adipocyte and consequently accumulates excess fat. There are many ways to control obesity; (i) reduce the uptake of high calorie food, (ii) proper exercise, and (iii) block the differentiation of stem cells into adipocytes.
Statin compounds have been reported block preadipocyte (3T3-L1) differentiated into adipocyte and 2-deoxyglucose has been reported to reduce glucose metabolism in vivo. It has been also demonstrated that stem cell isolated from human adipose tissue is a mesenchymal lineage cell and it can be differentiated into adipocyte. In this report, we chose human adipose tissue derived stem cell as a model system to study the anti-adipogenic effects of statin compounds and 2-deoxy glucose. The results showed that both statin compounds and 2-deoxy glucose have anti-adipogenic activities.

李政昕。脂肪組織中獲取具全能性幹細胞：應用在聚乳酸-聚乙醇酸共聚物三度立體支架之骨組織工程。國立成功大學生科所碩士論文，（民91年）。

J. Aubert, N. Belmonte, and C. Dani, "Role of pathways for signal transducers and activators of transcription, and mitogen-activated protein kinase in adipocyte differentiation," Cell Mol Life Sci 56(5-6), 538-542 (1999).

B. V. Bassa, D. D. Roh, N. D. Vaziri, M. A. Kirschenbaum, and V. S. Kamanna, "Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells," Biochim Biophys Acta 1449(2), 137-149 (1999).

Q. Cui, G. J. Wang, C. C. Su, and G. Balian, "The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis," Clin Orthop (344), 8-19 (1997).

L. Fajas, K. Schoonjans, L. Gelman, J. B. Kim, J. Najib, G. Martin, J. C. Fruchart, M. Briggs, B. M. Spiegelman, and J. Auwerx, "Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism," Mol Cell Biol 19(8), 5495-5503 (1999).

B. Gauthier, M. Robb, and R. McPherson, "Cholesteryl ester transfer protein gene expression during differentiation of human preadipocytes to adipocytes in primary culture," Atherosclerosis 142(2), 301-307 (1999).

F. M. Gregoire, C. M. Smas, and H. S. Sul, "Understanding adipocyte differentiation," Physiol Rev 78(3), 783-809 (1998).

A. H. Hasty, H. Shimano, N. Yahagi, M. Amemiya-Kudo, S. Perrey, T. Yoshikawa, J. Osuga, H. Okazaki, Y. Tamura, Y. Iizuka, F. Shionoiri, K. Ohashi, K. Harada, T. Gotoda, R. Nagai, S. Ishibashi, and N. Yamada, "Sterol regulatory element-binding protein-1 is regulated by glucose at the transcriptional level," J Biol Chem 275(40), 31069-31077 (2000).

K. A. Kelly and J. M. Gimble, "1,25-Dihydroxy vitamin D3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures," Endocrinology 139(5), 2622-2628 (1998).

K. M. Kras, D. B. Hausman, G. J. Hausman, and R. J. Martin, "Adipocyte development is dependent upon stem cell recruitment and proliferation of preadipocytes," Obes Res 7(5), 491-497 (1999).

T. F. McGuire, X. Q. Xu, S. J. Corey, G. G. Romero, and S. M. Sebti, "Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity," Biochem Biophys Res Commun 204(1), 399-406 (1994).

H. Mizuno, P. A. Zuk, M. Zhu, H. P. Lorenz, P. Benhaim, and M. H. Hedrick, "Myogenic differentiation by human processed lipoaspirate cells," Plast Reconstr Surg 109(1), 199-209; discussion 210-191 (2002).

W. M. Mueller, F. M. Gregoire, K. L. Stanhope, C. V. Mobbs, T. M. Mizuno, C. H. Warden, J. S. Stern, and P. J. Havel, "Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes," Endocrinology 139(2), 551-558 (1998).

E. Nishio, K. Tomiyama, H. Nakata, and Y. Watanabe, "3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor impairs cell p4fferentiation in cultured adipogenic cells (3T3-L1)," Eur J Pharmacol 301(1-3), 203-206 (1996).

J. Pairault and H. Green, "A study of the adipose conversion of suspended 3T3 cells by using glycerophosphate dehydrogenase as differentiation marker," Proc Natl Acad Sci U S A 76(10), 5138-5142 (1979).

O. V. Pavlov, V. Bobryshev Yu, V. Balabanov Yu, and K. Ashwell, "An in vitro study of the effects of lovastatin on human fetal brain cells," Neurotoxicol Teratol 17(1), 31-39 (1995).

S. M. Rangwala and M. A. Lazar, "Transcriptional control of adipogenesis," Annu Rev Nutr 20, 535-559 (2000).

R. Roduit, J. Morin, F. Masse, L. Segall, E. Roche, C. B. Newgard, F. Assimacopoulos-Jeannet, and M. Prentki, "Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta -cell," J Biol Chem 275(46), 35799-35806 (2000).

E. D. Rosen and B. M. Spiegelman, "Molecular regulation of adipogenesis," Annu Rev Cell Dev Biol 16, 145-171 (2000).

K. M. Safford, K. C. Hicok, S. D. Safford, Y. D. Halvorsen, W. O. Wilkison, J. M. Gimble, and H. E. Rice, "Neurogenic differentiation of murine and human adipose-derived stromal cells," Biochem Biophys Res Commun 294(2), 371-379 (2002).

V. Sottile and K. Seuwen, "A high-capacity screen for adipogenic differentiation," Anal Biochem 293(1), 124-128 (2001).

J. Suga, Y. Yoshimasa, K. Yamada, Y. Yamamoto, G. Inoue, M. Okamoto, T. Hayashi, M. Shigemoto, A. Kosaki, H. Kuzuya, and K. Nakao, "Differential activation of mitogen-activated protein kinase by insulin and epidermal growth factor in 3T3-L1 adipocytes: a possible involvement of PI3-kinase in the activation of the MAP kinase by insulin," Diabetes 46(5), 735-741 (1997).

K. Tomiyama, H. Nakata, H. Sasa, S. Arimura, E. Nishio, and Y. Watanabe, "Wortmannin, a specific phosphatidylinositol 3-kinase inhibitor, inhibits adipocytic differentiation of 3T3-L1 cells," Biochem Biophys Res Commun 212(1), 263-269 (1995).

K. Tomiyama, E. Nishio, and Y. Watanabe, "Both wortmannin and simvastatin inhibit the adipogenesis in 3T3-L1 cells during the late phase of differentiation," Jpn J Pharmacol 80(4), 375-378 (1999).

G. J. Wang, Q. Cui, and G. Balian, "The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis," Clin Orthop (370), 295-310 (2000).

P. A. Zuk, M. Zhu, P. Ashjian, D. A. De Ugarte, J. I. Huang, H. Mizuno, Z. C. Alfonso, J. K. Fraser, P. Benhaim, and M. H. Hedrick, "Human adipose tissue is a source of multipotent stem cells," Mol Biol Cell 13(12), 4279-4295 (2002).

P. A. Zuk, M. Zhu, H. Mizuno, J. Huang, J. W. Futrell, A. J. Katz, P. Benhaim, H. P. Lorenz, and M. H. Hedrick, "Multilineage cells from human adipose tissue: implications for cell-based therapies," Tissue Eng 7(2), 211-228 (2001).